Kintor 0.9% , save your money friends
    Minoxidil 3/23/2026

    New to Pyrilutamide? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💧 Kintor (topical) 0.9% 5-6 days a week over a year
    💧 pyrilutamide (topical) 0.5% every other day
    the tone is 😞 negative with not effective results.

    Other terms

    Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Anyone who used RU58841 without fin/dut?

      in Product  1 upvotes 1 year ago
      RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

      community when is kintor going to start phase 3 for gt20029?

       6 upvotes 2 years ago
      The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

      community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

       17 upvotes 4 years ago
      People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

       124 upvotes 2 years ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

    Related Research

    6 / 6 results
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Development and Validation of Androgen-Induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      research Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents

      1 citations , April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences”
      This study evaluated androgen-induced hair loss and anagen induction mouse models, finding that Minoxidil and Pyrilutamide significantly promoted hair growth by decreasing androgen receptor protein levels and enhancing the Wnt/β-Catenin signaling pathway, supporting their use in studying novel treatments for androgenetic alopecia.
      Androgenetic Alopecia: Therapy Update

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
      A Decade of Progress in Androgenetic Alopecia Management: Emerging Therapies and Multimodal Strategies

      research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies

      December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology”
      This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
      Androgenetic Alopecia: A Literature Review

      research Androgenetic alopecia - a literature review

      June 2025 in “Journal of Education Health and Sport”
      This review highlights that while finasteride and minoxidil effectively treat androgenetic alopecia, emerging options like dutasteride, mesotherapy, androgen blockers, and red LED therapy show promising results, especially when used in combination, though further research is needed for standardization and safety confirmation.